318 related articles for article (PubMed ID: 23204401)
21. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
22. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.
Rose KL; Paixao-Cavalcante D; Fish J; Manderson AP; Malik TH; Bygrave AE; Lin T; Sacks SH; Walport MJ; Cook HT; Botto M; Pickering MC
J Clin Invest; 2008 Feb; 118(2):608-18. PubMed ID: 18202746
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
24. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
[TBL] [Abstract][Full Text] [Related]
25. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
Xiao X; Pickering MC; Smith RJ
Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
[TBL] [Abstract][Full Text] [Related]
26. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.
Martínez-Barricarte R; Heurich M; Valdes-Cañedo F; Vazquez-Martul E; Torreira E; Montes T; Tortajada A; Pinto S; Lopez-Trascasa M; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
J Clin Invest; 2010 Oct; 120(10):3702-12. PubMed ID: 20852386
[TBL] [Abstract][Full Text] [Related]
27. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy.
Zanchi C; Locatelli M; Cerullo D; Aumiller V; Corna D; Rottoli D; Eisermann M; Donadelli R; Mousavi M; Noris M; Remuzzi G; Benigni A; Zoja C
J Immunol; 2022 Apr; 208(7):1772-1781. PubMed ID: 35277417
[TBL] [Abstract][Full Text] [Related]
29. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
30. C3 Glomerulonephritis With Multiple Mutations in Complement Factor H.
Dalili N; Behnam B; Vali F; Parvin M; Torbati P; Rasaii N; Samadian F; Ahmadpoor P
Iran J Kidney Dis; 2018 Nov; 12(6):376-381. PubMed ID: 30595568
[TBL] [Abstract][Full Text] [Related]
31. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
32. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far.
Larsen CP; Walker PD
Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589
[No Abstract] [Full Text] [Related]
33. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
Zhang Y; Keenan A; Dai DF; May KS; Anderson EE; Lindorfer MA; Henrich JB; Pitcher GR; Taylor RP; Smith RJ
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376801
[TBL] [Abstract][Full Text] [Related]
34. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
Besbas N; Gulhan B; Gucer S; Korkmaz E; Ozaltin F
J Nephrol; 2014 Aug; 27(4):457-60. PubMed ID: 24536001
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
[No Abstract] [Full Text] [Related]
36. Complement and diseases: defective alternative pathway control results in kidney and eye diseases.
Zipfel PF; Heinen S; Józsi M; Skerka C
Mol Immunol; 2006 Jan; 43(1-2):97-106. PubMed ID: 16026839
[TBL] [Abstract][Full Text] [Related]
37. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.
Pickering MC; Cook HT; Warren J; Bygrave AE; Moss J; Walport MJ; Botto M
Nat Genet; 2002 Aug; 31(4):424-8. PubMed ID: 12091909
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.
Pickering MC; de Jorge EG; Martinez-Barricarte R; Recalde S; Garcia-Layana A; Rose KL; Moss J; Walport MJ; Cook HT; de Córdoba SR; Botto M
J Exp Med; 2007 Jun; 204(6):1249-56. PubMed ID: 17517971
[TBL] [Abstract][Full Text] [Related]
40. Classical complement pathway activation in membranoproliferative glomerulonephritis.
Ooi YM; Vallota EH; West CD
Kidney Int; 1976 Jan; 9(1):46-53. PubMed ID: 781380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
